Effectiveness of BNT162b2 and CoronaVac vaccines against omicron in children aged 5 to 11 years.

ABSTRACT:

Background

This study aimed to estimate vaccine effectiveness (VE) against omicron variant infection and severe corona virus disease 2019 (COVID-19) in children aged 5-11 years hospitalized with acute respiratory syndrome.

Methods

A test-negative, case-control analysis was conducted from February 2022 to June 2022. We enrolled 6950 eligible children, including 1102 cases and 5848 controls. VE was calculated after immunization with one and two doses of BNT162b2 or CoronaVac. The outcomes were hospitalization with acute respiratory symptoms and detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe COVID-19. The adjusted odds ratio for the association of prior vaccination and outcomes was used to estimate VE.

Results

For fully vac

SUBMITTER: Oliveira EA 

PROVIDER: S-EPMC10010648 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature